
Olivia Wagemann, MD
Postdoctoral Research Associate; DIAN Trials Unit
- Email: oliviaw@nospam.wustl.edu
2022-2023
Olivia Wagemann earned her medical degree at the University of Regensburg (Germany) in 2020, where she also obtained her thesis in the field of translational cardiology, investigating the effect of SGLT2-inhibition on ion homeostasis in models of murine and human heart failure.
She is now a neurology resident in training at the LMU University Munich (Germany) and specializes in clinical research of neurodegenerative diseases. Her primary interests include Alzheimer’s Disease in adults with Down-Syndrome as well as evaluating sociocultural and care-related influences on diagnosis and prognosis in patients with dementia. Through her comprehensive work in the Outpatient Clinic for Clinical Neurodegeneration at the LMU and the German Centre for Neurodegenerative Diseases (DZNE), she is strongly involved in phenotyping of patients with Alzheimer’s Dementia and Frontotemporal Dementia and has gathered experience in project organization and study coordination.
Contributions to science:
Oeckl P*, Wagemann O*, Halbgebauer S, Anderl-Straub S, Nuebling G, Prix C, Loosli SV, Wlasich E, Danek A, Steinacker P, Ludolph AC, Levin J°, Otto M°. Serum Beta-Synuclein is higher in Down syndrome and precedes rise of pTau181. Ann Neurol. 2022. doi:10.1002/ana.26360
Wagemann O, Loosli S., Vöglein J, Prix C, Wlasich E, Nübling G, Danek A, Levin J. Regression in Young Adults with Down Syndrome: A Case Series. Fortschr Neurol Psychiatr. 2022. doi:10.1055/a-1743-2915
Nübling G, Wagemann O, Loosli SV, Wlasich E, Danek A, Levin J. Diagnosing Alzheimer Dementia in People with Down Syndrome in Accordance with ICD, DSM V and A/T/N System. Fortschr Neurol Psychiatr. 2022. doi:10.1055/a-1771-6273
Wagemann O, Danek A. (2022). Differential Diagnosis in Dementia. PSYCH up2date. 2022. doi:10.1055/a-1148-7228
Mustroph J, Wagemann O, Lücht CM, Trum M, Hammer KP, Sag CM, Lebek S, Tarnowski D, Reinders J, Perbellini F, Terracciano C, Schmid C, Schopka S, Hilker M, Zausig Y, Pabel S, Sossalla ST, Schweda F, Maier LS, Wagner S. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018. doi:10.1002/ehf2.12336
Mustroph J, Wagemann O, Lebek S, Tarnowski D, Ackermann J, Drzymalski M, Pabel S, Schmid C, Wagner S, Sossalla S, Maier LS, Neef S. SR Ca2+-leak and disordered excitation-contraction coupling as the basis for arrhythmogenic and negative inotropic effects of acute ethanol exposure. J Mol Cell Cardiol. 2018. doi: 10.1016/j.yjmcc.2018.02.002